Overview

This trial is active, not recruiting.

Condition coronary heart disease
Sponsor Cardiovascular Institute & Fuwai Hospital
Collaborator Ministry of Science and Technology of the People´s Republic of China
Start date February 2012
End date October 2013
Trial size 400 participants
Trial identifier NCT01543308, 2011-HDL-01

Summary

The protein composition of HDL is complicated. The investigators have identified 40 distinct proteins associated with HDL by proteomics technology, and these proteins have been confirmed to be related to the function of anti-inflammation, anti-oxidation, improvement of endothelial function, inhibition of thrombosis and so on. And the investigators also found that the levels of some proteins in HDL changed in patients with coronary heart disease, compared with the healthy control group.

So, this study is to conduct in the two following aspects: enlarge the sample size to verify the preliminary results to find new research ideas of pathogenesis and biomarkers for coronary heart disease; and study the changes of HDL protein composition in patients with coronary heart disease before and after statins treatment using proteomics technology in order to find the mechanism of statins pleiotropic effects and indicators for evaluating the treatment effectiveness.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Arm

Primary Outcomes

Measure
Differential Proteins and the levels of Differential Proteins
time frame: up to 3 years

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: Angiographic evidence of coronary artery disease, and no lipid-lowering therapy in the past 2 weeks for treatment group; Exclusion Criteria: - Use of potent lipid-lowering therapy for more than 2 weeks; myocardial infarction or percutaneous coronary intervention in the past 6 months; severe congestive heart failure, valvular heart disease and other non-coronary heart disease cardiovascular disease; liver or renal dysfunction; connective tissue disease; infection, Malignancy; and other conditions that physicians considered inappropriate to the study.

Additional Information

Official title Phase 1 Study of Coronary Heart Disease Proteomics Research
Principal investigator Hong Liu
Trial information was received from ClinicalTrials.gov and was last updated in May 2013.
Information provided to ClinicalTrials.gov by Cardiovascular Institute & Fuwai Hospital.